GuidelineZeitschrift fur Rheumatologie2018
[S3 guidelines on treatment of polymyalgia rheumatica : Evidence-based guidelines of the German Society of Rheumatology (DGRh), the Austrian Society of Rheumatology and Rehabilitation (ÖGR) and the Swiss Society of Rheumatology (SGT) and participating medical scientific specialist societies and other organizations].
Guideline in Zeitschrift fur Rheumatologie, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Guideline
- Frequency, diagnosis, and management of polymyalgia rheumatica in Germany-database analysis of medical insurance data.Rheumatology (Oxford, England) · 2025Article
- Methotrexate - Safe Backbone for the Treatment of Rheumatoid Arthritis.Current rheumatology reviews · 2025Review
- [Rheumatological care in Germany : Memorandum of the German Society for Rheumatology and Clinical Immunology 2024].Zeitschrift fur Rheumatologie · 2024Article
- Magnetic resonance imaging in polymyalgia rheumatica-contrast enhancement is not always needed.Zeitschrift fur Rheumatologie · 2024Article
- [Sarilumab for polymyalgia rheumatica].Zeitschrift fur Rheumatologie · 2024Article
- In Reply.Deutsches Arzteblatt international · 2023Article
- Polymyalgia Rheumatica.Deutsches Arzteblatt international · 2022Review
- [Chronic inflammatory demyelinating polyneuropathy as differential diagnosis to polymyalgia rheumatica].Zeitschrift fur Rheumatologie · 2022Article
- [This is how I treat-Polymyalgia rheumatica with a cumulative dosage of glucocorticoids as low as possible].Zeitschrift fur Rheumatologie · 2022Article
- [Glucocorticoid-induced osteoporosis-Focus treatment (part 1)].Zeitschrift fur Rheumatologie · 2022Article
- Vessel Wall Inflammatory Activity as Determined by F-18 Fluorodeoxyglucose PET in Large Vessel Vasculitis Is Attenuated by Immunomodulatory Drugs.Diagnostics (Basel, Switzerland) · 2021Article
- [68/f-Muscle stiffness-like pain for 3 weeks : Preparation for the medical specialist examination: part 34].Der Internist · 2021Article
- [S2k guidelines: management of large-vessel vasculitis].Zeitschrift fur Rheumatologie · 2020Review
- [Treatment of giant cell arteritis and polymyalgia rheumatica].Zeitschrift fur Rheumatologie · 2020Article
- [Oral glucocorticoids : Therapeutic use and treatment monitoring in inflammatory rheumatic diseases].Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete · 2020Article
- [Oral glucocorticoids : Therapeutic use and treatment monitoring in inflammatory rheumatic diseases].Zeitschrift fur Rheumatologie · 2019Review
- [Rheumatological care in the Rheumazentrum Ruhrgebiet Rheumatism Center-a model for conurbations].Zeitschrift fur Rheumatologie · 2019Review
- [Promotion of physical activity for older patients with rheumatism : Characteristics of inflammatory rheumatic diseases against the background of physical activity recommendations].Zeitschrift fur Rheumatologie · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polymyalgia rheumatica (PMR) occurs almost exclusively in persons aged 50 years or older and it is the second most common inflammatory rheumatic disease in older people after rheumatoid arthritis. Since there are no specific tests for PMR, the exclusion of clinically similar differential diagnoses is essential to ascertain the diagnosis. These recommendations for the management of PMR assume an already established diagnosis of PMR. It is recommended to initiate treatment with glucocorticoids immediately after diagnosis and to provide appropriate patient information and education about the impact of the disease and its treatment. Methotrexate should be considered in patients at high risk for relapse and/or glucocorticoid-related adverse events. These guidelines have been elaborated because there is significant heterogeneity in the management of PMR in clinical practice in Germany (but also Europe and worldwide), despite the large number of patients with this disease. These guidelines are primarily based on the 2015 EULAR-ACR recommendations for the management of PMR, which were updated by the guideline committee and adapted to the German speaking countries.
Indexed as
Identifiers
29845555What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.